BR0109814A - Derivados de indolin-2-ona e sua utilização como ligantes dos receptores da ocitocina - Google Patents
Derivados de indolin-2-ona e sua utilização como ligantes dos receptores da ocitocinaInfo
- Publication number
- BR0109814A BR0109814A BR0109814-4A BR0109814A BR0109814A BR 0109814 A BR0109814 A BR 0109814A BR 0109814 A BR0109814 A BR 0109814A BR 0109814 A BR0109814 A BR 0109814A
- Authority
- BR
- Brazil
- Prior art keywords
- indolin
- derivatives
- oxytocin receptor
- receptor binders
- binders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0004193A FR2807038B1 (fr) | 2000-04-03 | 2000-04-03 | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
PCT/FR2001/000980 WO2001074775A1 (fr) | 2000-04-03 | 2001-04-02 | Derives d'indolin-2-one et leur utilisation en tant que ligands des recepteurs de l'ocytocine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0109814A true BR0109814A (pt) | 2003-01-21 |
Family
ID=8848777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0109814-4A BR0109814A (pt) | 2000-04-03 | 2001-04-02 | Derivados de indolin-2-ona e sua utilização como ligantes dos receptores da ocitocina |
Country Status (35)
Country | Link |
---|---|
US (2) | US20040059132A1 (pt) |
EP (1) | EP1272468B1 (pt) |
JP (1) | JP2003529586A (pt) |
KR (1) | KR100765028B1 (pt) |
CN (1) | CN1224614C (pt) |
AR (1) | AR034547A1 (pt) |
AT (1) | ATE282593T1 (pt) |
AU (2) | AU2001246671B2 (pt) |
BR (1) | BR0109814A (pt) |
CA (1) | CA2404592A1 (pt) |
CZ (1) | CZ20023297A3 (pt) |
DE (1) | DE60107221T2 (pt) |
DK (1) | DK1272468T3 (pt) |
EA (1) | EA005093B1 (pt) |
EE (1) | EE05002B1 (pt) |
ES (1) | ES2232610T3 (pt) |
FR (1) | FR2807038B1 (pt) |
HK (1) | HK1050004A1 (pt) |
HU (1) | HUP0303109A3 (pt) |
IL (1) | IL152085A0 (pt) |
IS (1) | IS2458B (pt) |
ME (1) | MEP24308A (pt) |
MX (1) | MXPA02009773A (pt) |
NO (1) | NO324314B1 (pt) |
NZ (1) | NZ521617A (pt) |
PL (1) | PL358222A1 (pt) |
PT (1) | PT1272468E (pt) |
SI (1) | SI1272468T1 (pt) |
SK (1) | SK14272002A3 (pt) |
TR (1) | TR200202288T2 (pt) |
TW (1) | TWI225860B (pt) |
UA (1) | UA73163C2 (pt) |
WO (1) | WO2001074775A1 (pt) |
YU (1) | YU80902A (pt) |
ZA (1) | ZA200207802B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60333857D1 (de) * | 2002-10-03 | 2010-09-30 | Neuropharmacology Services Llc | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
FR2875499B1 (fr) | 2004-09-20 | 2006-10-27 | Sanofi Aventis Sa | Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
AU2006244693B2 (en) * | 2005-05-10 | 2010-11-04 | Ferring International Center Sa. | Use of antagonists of oxytocin and/or vasopressin in assisted reproduction |
CN101336239A (zh) * | 2005-12-02 | 2008-12-31 | 艾博特股份有限两合公司 | 经取代的羟吲哚衍生物,含有该衍生物的药物及其用途 |
US7855194B2 (en) | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
WO2007120102A1 (en) * | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
FR2909668B1 (fr) * | 2006-12-12 | 2009-01-23 | Sanofi Aventis Sa | Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique |
EP2350090B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
MY179342A (en) | 2009-10-14 | 2020-11-04 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
CN103623268B (zh) * | 2013-12-04 | 2015-07-15 | 张国显 | 神经康复再造丸及其制备方法 |
CN103830666B (zh) * | 2014-02-14 | 2016-02-10 | 孔祥英 | 一种治疗高血压的中药足浴组合物 |
CN104402886B (zh) * | 2014-09-18 | 2017-01-25 | 陕西科技大学 | 一种具有抗肿瘤活性的7‑氮杂靛红类双螺环化合物及其合成方法 |
CN104230786B (zh) * | 2014-09-26 | 2017-03-22 | 陕西科技大学 | 一种具有抗肿瘤活性的含吲哚结构的化合物及其合成方法 |
AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
EP3371168B1 (en) | 2015-11-06 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
MA43799A (fr) * | 2016-01-20 | 2021-03-31 | Chemocentryx Inc | Composés de 2-oxindole |
CN109232290A (zh) * | 2018-11-07 | 2019-01-18 | 陕西科技大学 | 一种含氟酰胺及其制备方法 |
CN109678781B (zh) * | 2018-12-20 | 2022-03-29 | 苏州麦迪耐斯医药科技有限公司 | 一种刺猬通路抑制剂 |
EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3529994A1 (de) * | 1985-08-22 | 1987-02-26 | Hoechst Ag | Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
ES2110965T3 (es) * | 1989-07-25 | 1998-03-01 | Taiho Pharmaceutical Co Ltd | Derivado de oxoindol. |
FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
JPH10338672A (ja) * | 1996-07-16 | 1998-12-22 | Takeda Chem Ind Ltd | 排尿調節剤および2環性化合物 |
-
2000
- 2000-04-03 FR FR0004193A patent/FR2807038B1/fr not_active Expired - Fee Related
-
2001
- 2001-02-04 UA UA2002097763A patent/UA73163C2/uk unknown
- 2001-03-30 AR ARP010101541A patent/AR034547A1/es unknown
- 2001-04-02 MX MXPA02009773A patent/MXPA02009773A/es active IP Right Grant
- 2001-04-02 SI SI200130294T patent/SI1272468T1/xx unknown
- 2001-04-02 PL PL01358222A patent/PL358222A1/xx not_active Application Discontinuation
- 2001-04-02 HU HU0303109A patent/HUP0303109A3/hu unknown
- 2001-04-02 CZ CZ20023297A patent/CZ20023297A3/cs unknown
- 2001-04-02 AT AT01919610T patent/ATE282593T1/de active
- 2001-04-02 SK SK1427-2002A patent/SK14272002A3/sk unknown
- 2001-04-02 CN CNB018090303A patent/CN1224614C/zh not_active Expired - Fee Related
- 2001-04-02 DE DE60107221T patent/DE60107221T2/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013217A patent/KR100765028B1/ko not_active IP Right Cessation
- 2001-04-02 DK DK01919610T patent/DK1272468T3/da active
- 2001-04-02 AU AU2001246671A patent/AU2001246671B2/en not_active Ceased
- 2001-04-02 JP JP2001572470A patent/JP2003529586A/ja active Pending
- 2001-04-02 AU AU4667101A patent/AU4667101A/xx active Pending
- 2001-04-02 CA CA002404592A patent/CA2404592A1/fr not_active Abandoned
- 2001-04-02 TR TR2002/02288T patent/TR200202288T2/xx unknown
- 2001-04-02 WO PCT/FR2001/000980 patent/WO2001074775A1/fr active IP Right Grant
- 2001-04-02 BR BR0109814-4A patent/BR0109814A/pt not_active IP Right Cessation
- 2001-04-02 YU YU80902A patent/YU80902A/sh unknown
- 2001-04-02 EA EA200200912A patent/EA005093B1/ru not_active IP Right Cessation
- 2001-04-02 ES ES01919610T patent/ES2232610T3/es not_active Expired - Lifetime
- 2001-04-02 IL IL15208501A patent/IL152085A0/xx not_active IP Right Cessation
- 2001-04-02 PT PT01919610T patent/PT1272468E/pt unknown
- 2001-04-02 EP EP01919610A patent/EP1272468B1/fr not_active Expired - Lifetime
- 2001-04-02 ME MEP-243/08A patent/MEP24308A/xx unknown
- 2001-04-02 EE EEP200200573A patent/EE05002B1/xx not_active IP Right Cessation
- 2001-04-02 NZ NZ521617A patent/NZ521617A/en not_active IP Right Cessation
- 2001-04-03 TW TW090107916A patent/TWI225860B/zh not_active IP Right Cessation
-
2002
- 2002-09-24 IS IS6566A patent/IS2458B/is unknown
- 2002-09-27 ZA ZA200207802A patent/ZA200207802B/en unknown
- 2002-10-02 NO NO20024749A patent/NO324314B1/no not_active IP Right Cessation
-
2003
- 2003-03-26 HK HK03102206A patent/HK1050004A1/xx not_active IP Right Cessation
- 2003-09-03 US US10/654,060 patent/US20040059132A1/en not_active Abandoned
-
2007
- 2007-05-03 US US11/744,003 patent/US20070203184A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0109814A (pt) | Derivados de indolin-2-ona e sua utilização como ligantes dos receptores da ocitocina | |
BR0115580A (pt) | Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2 | |
BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
BR9911013A (pt) | Derivados de pirazol como inibidores da p-38 map quinase | |
BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
BR0206955A (pt) | Ligantes de receptores de canabinóides | |
BRPI0113162B8 (pt) | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos | |
BRPI0507877A (pt) | derivados de formamida, composição farmacêutica, uso dos mesmos e combinação | |
PT1254134E (pt) | Derivados de 1,3-di-hidro-2h-indol-2-ona e sua utilizacao como ligandos para os receptores v1b ou v1b e v1a da arginina-vasopressina | |
TR200101961T2 (tr) | 1,2-halkalı kinolin türevleri | |
BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
BR0108678A (pt) | Novos compostos | |
SE0302760D0 (sv) | New compounds | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
HN2002000300A (es) | Nuevos derivados de piperazina | |
ES2183180T3 (es) | Nuevos derivados de guanidina, procedimientos para su preparacion y su uso como medicamento. | |
BR0310077A (pt) | Novos compostos e sua utilização | |
ES2178055T3 (es) | Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
ES2189489T3 (es) | Uso de derivados n-acilvainillinamidicos como agonistas de receptores cb1 perifericos de cannabinoides. | |
BRPI0409465A (pt) | derivados de carboxamida como agentes antidiabéticos | |
HN2001000235A (es) | Derivados puentes de piperazina | |
BR0012478A (pt) | Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos | |
BR9814951A (pt) | Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto | |
BRPI0411729A (pt) | dicetopiperazinas substituìdas e seu uso como antagonistas da oxitocina | |
BR0215272A (pt) | Derivados imidazoquinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS (FR) Free format text: ALTERADO DE: SANOFI-SYNTHELABO |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A E 13A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 12A, 13A, 14A, 15A, 16A, 17A, 18A E 19A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |